Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    +1.76 (+2.16%)
     
  • Gold

    2,254.80
    +42.10 (+1.90%)
     
  • Silver

    25.10
    +0.35 (+1.41%)
     
  • EUR/USD

    1.0792
    -0.0037 (-0.35%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2624
    -0.0014 (-0.11%)
     
  • USD/JPY

    151.3580
    +0.1120 (+0.07%)
     
  • Bitcoin USD

    70,811.90
    +1,713.92 (+2.48%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Hyperion stops diabetes drug development

Sept 8 (Reuters) - Hyperion Therapeutics Inc said it would stop development of its diabetes drug, after the company discovered that certain employees of its recently acquired subsidiary engaged in unlawful conduct.

Employees of the Israeli drug developer, Andromeda Biotech Ltd, which Hyperion acquired in June, engaged in serious misconduct that involved receiving unblinded data from the trial and manipulating it to obtain a favorable result, Hyperion said.

(Reporting by Natalie Grover in Bangalore; Editing by Sriraj Kalluvila)

Advertisement